Abstract

The Clinical Trials Research Office (CTRO) provides the infrastructure and facilitates the coordination necessary to support high quality clinical research in a matrix style cancer center. The science supported by the CTRO encompasses all levels and types of clinical trials, from pilot studies and phase I protocols through phase II and III protocols. These protocols may be UWCCC investigator-initiated institutional or industry sponsored clinical trials, or they may be NCI-sponsored clinical trials funded through the cooperative group, phase I, or research grant mechanisms. The CTRO infrastructure for clinical research supported by the CCSG grant is designed to facilitate and promote clinical research by providing effective mechanisms for quality control and efficiency. The UWCCC core component of the CTRO provides a basic level of protocol- specific support for all UWCCC clinical trials. This includes process coordination; protocol activation and closure; tracking by the UWCCC data base; regulatory review and compliance; patient registration and randomization; and quality assurance. The CTRO supports the Protocol Review and Monitoring System, providing checkpoints for quality control and for enforcement of the institutional authority to open and close protocols. It ensures complete reports on protocol activity and meaningful cancer center supervision of the cancer clinical research in the institution.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014520-27S2
Application #
6217223
Study Section
Project Start
1999-04-16
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715

  Publications

Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Denu, Ryan A; Shabbir, Maria; Nihal, Minakshi et al. (2018) Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res 16:517-527
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Ong, Irene M; Gonzalez, Jose G; McIlwain, Sean J et al. (2018) Gut microbiome populations are associated with structure-specific changes in white matter architecture. Transl Psychiatry 8:6
Trentham-Dietz, Amy; Ergun, Mehmet Ali; Alagoz, Oguzhan et al. (2018) Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. Breast Cancer Res Treat 168:229-239
Weiss, Jennifer M; Pandhi, Nancy; Kraft, Sally et al. (2018) Primary care colorectal cancer screening correlates with breast cancer screening: implications for colorectal cancer screening improvement interventions. Clin Transl Gastroenterol 9:148
Bruce, Jordan G; Tucholka, Jennifer L; Steffens, Nicole M et al. (2018) Feasibility of Providing Web-Based Information to Breast Cancer Patients Prior to a Surgical Consult. J Cancer Educ 33:1069-1074
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:

Showing the most recent 10 out of 1528 publications